Sequential steroid hormone receptor measurements in primary breast cancer with and without intervening primary chemotherapy

Endocrine-Related Cancer

Volumn 10, Issue 1, 2003, Pages 91-98

  Taucher, S ^a   Rudas, M ^a   Gnant, M ^a   Thomanek, K ^a   Dubsky, P ^a   Roka, S ^a   Bachleitner, T ^a   Kandioler, D ^a   Wenzel, C ^a   Steger, G ^a   Mittlbock M ^a   Jakesz, R ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; HORMONE; METHOTREXATE; PROGESTERONE RECEPTOR; STEROID RECEPTOR; TAXANE DERIVATIVE;

ADULT; AGED; ARTICLE; BREAST BIOPSY; BREAST CARCINOMA; BREAST SURGERY; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER HORMONE THERAPY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FEMALE; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; NEEDLE BIOPSY; PREOPERATIVE CARE; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MIDDLE AGED; NEOPLASM STAGING; PREOPERATIVE CARE; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 1642421051     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.0.0100091     Document Type: Article

References (33)

1. Allegra JC, Lippman ME, Thompson EB, Simon R, Barlock A, Green L, Huff KK, Do HM, Aitken SC & Warren R 1980 Estrogen receptor status: an important variable in predicting response to endocrine therapy in metastatic breast cancer. European Journal of Cancer 16 323-331.
2. Allred DC, Harvey JM, Berardo M & Clark GM 1998 Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Modern Pathology 11 155-168.
3. Bottini A, Berruti A, Bersiga A, Brunelli A, Brizzi MP, Marco BD, Cirillo F, Bolsi G, Bertoli G, Alquati P & Dogliotti L 1996 Effect of neoadjuvant chemotherapy on Ki67 labelling index, c-erbB-2 expression and steroid hormone receptor status in human breast tumours. Anticancer Research 16 3105-3110.
4. Chang J, Powles TJ, Allred DC, Ashley SE, Clark GM, Makris A, Assersohn L, Gregory RK, Osborne CK & Dowsett M 1999 Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer. Journal of Clinical Oncology 17 3058-3063.
5. Chen GC, Guan LS, Hu WL & Wang ZY 2002 Functional repression of estrogen receptor a by arsenic trioxide in human breast cancer cells. Anticancer Research 22 633-638.
6. Clark GM 1996 Prognostic and predictive factors. In Diseases of the Breast, pp 461-485. Eds JR Harris, ME Lippman, M Morrow & S Hellman. Philadelphia, USA: Lippincott-Raven.
7. Cohen J 1960 A coefficient of agreement for nominal scales. Educational and Psychological Measurement 20 37-46.
8. Di Loreto C, Puglisi F, Rimondi G, Zuiani C, Anania G, Della Mea V & Beltrami CA 1996 Large core biopsy for diagnostic and prognostic evaluation of invasive breast carcinomas. European Journal of Cancer 32A 1693-1700.
9. Early Breast Cancer Trialists' Collaborative Group 1998a Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 351 1451-1467.
10. Early Breast Cancer Trialists' Collaborative Group 1998b Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 352 930-942.
11. Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER, Wickerham DL, Begovic M, DeCillis A, Robidoux A, Margolese RG, Cruz AB Jr, Hoehn JL, Lees AW, Dimitrov NV & Bear HD 1998 Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. Journal of Clinical Oncology 16 2672-2685.
12. Frassoldati A, Adami F, Banzi C, Criscuolo M, Piccinini L & Silingardi V 1997 Changes of biological features in breast cancer cells determined by primary chemotherapy. Breast Cancer Research and Treatment 44 185-192.
13. Harvey JM, Clark GM, Osborne CK & Allred DC 1999 Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. Journal of Clinical Oncology 17 1474-1481.
14. Hawkins RA, Tesdale AL, Anderson ED, Levack PA, Chetty U & Forrest AP 1990 Does the oestrogen receptor concentration of a breast cancer change during systemic therapy? British Journal of Cancer 61 877-880.
15. Hayward JL, Carbone PP, Heuson JC, Kumaoka S, Segaloff A & Rubens RD 1977 Assessment of response to therapy in advanced breast cancer: a project of the Programme on Clinical Oncology of the International Union Against Cancer, Geneva, Switzerland. Cancer 39 1289-1294.
16. Jakesz R 2001 Comparison of pre- vs. postoperative chemotherapy in breast cancer patients: four-year results of Austrian Breast & Colorectal Cancer Study Group (ABCSG) Trial 7. In Proceedings of the American Society of Clinical Oncology, San Francisco, USA, May 12-15, 32a.
17. Jakesz R, Hausmaninger H & Samonigg H 2002 Chemotherapy versus hormonal adjuvant treatment in premenopausal patients with breast cancer. European Journal of Cancer 38 327-332.
18. Landis RJ, Heyman ER & Koch GG 1978 Average partial association in three-way contingency tables: a review and discussion of alternative tests. International Statistical Review 46 237-254.
19. Lippman ME & Allegra JC 1980 Quantitative estrogen receptor analyses: the response to endocrine and cytotoxic chemotherapy in human breast cancer and the disease-free interval. Cancer 46 2829-2834.
20. McLeskey SW, Zhang L, El-Ashry D, Trock BJ, Lopez CA, Kharbanda S, Tobias CA, Lorant LA, Hannum RS, Dickson RB & Kern FG 1998 Tamoxifen-resistant fibroblast growth factor-transfected MCF-7 cells are cross-resistant in vivo to the antiestrogen ICI 182,780 and two aromatase inhibitors. Clinical Cancer Research 4 697-711.
21. Makris A, Powles TJ, Allred DC, Ashley SE, Trott PA, Ormerod MG, Titley JC & Dowsett M 1999 Quantitative changes in cytological molecular markers during primary medical treatment of breast cancer: a pilot study. Breast Cancer Research and Treatment 53 51-59.
22. Mouridsen H, Palshof T, Patterson J & Battersby L 1978 Tamoxifen in advanced breast cancer. Cancer Treatment Review 5 131-141.
23. Nicholson RI, McClelland RA, Findlay P, Eaton CL, Gullick WJ, Dixon AR, Robertson JF, Ellis IO & Blainey RW 1993 Relationship between EGF-R, c-erbβ-2 protein expression and Ki67 immunostaining in breast cancer and hormone sensitivity. European Journal of Cancer 7 1018-1023.
24. NIH 2001 National Institutes of Health Consensus Development Conference statement: adjuvant therapy for breast cancer, November 1-3 2000. Journal of the National Cancer Institute Monograph 30 5-15.
25. Oesterreich S, Zhang P, Guler RL, Sun X, Curran EM, Welshons WV, Osborne CK & Lee AV 2001 Re-expression of estrogen receptor alpha in estrogen receptor alpha-negative MCF-7 cells restores both estrogen and insulin-like growth factor-mediated signaling and growth. Cancer Research 61 5771-5777.
26. Regitnig P, Reiner A, Dinges HP, Hofler G, Muller-Holzner E, Lax SF, Obrist P, Rudas M & Quehenberger F 2002 Quality assurance for detection of estrogen and progesterone receptors by immunohistochemistry in Austrian pathology laboratories. Virchows Archive 441 328-334.
27. Reiner A, Neumeister B, Spona J, Reiner G, Schemper M & Jakesz R 1990 Immunocytochemical localization of estrogen and progesterone receptor and prognosis in human primary breast cancer. Cancer Research 50 7057-7061.
28. Robertson JF 1996 Oestrogen receptor: a stable phenotype in breast cancer. British Journal of Cancer 73 5-12.
29. Schneider J, Lucas R, Sanchez J, Ruibal A, Tejerina A & Martin M 2000 Modulation of molecular marker expression by induction chemotherapy in locally advanced breast cancer: correlation with the response to therapy and the expression of MDR1 and LRP. Anticancer Research 20 4373-4377.
30. Sharma AK, Horgan K, Douglas-Jones A, McClelland R, Gee J & Nicholson R 1994 Dual immunocytochemical analysis of oestrogen and epidermal growth factor receptors in human breast cancer. British Journal of Cancer 69 1032-1037.
31. Steger GG, Wenzel C, Schmidinger MP, Rudas M, Taucher S, Gnant MF & Jakesz R 2000 HER2-status predicts complete pathological response in primary, operable breast cancer treated with epirubicin, docetaxel + G-CSF, p 23. In San Antonio Breast Cancer Symposium, December 6-9, San Antonio, TX, USA. Ed ME Lippman.
32. Wilson MA & Chrysogelos SA 2002 Identification and characterization of a negative regulatory element within the epidermal growth factor receptor gene first intron in hormone-dependent breast cancer cells. Journal of Cellular Biochemistry 85 601-614.
33. Wolmark N, Wang J, Mamounas E, Bryant J & Fisher B 2001 Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. Journal of the National Cancer Institute Monograph 30 96-102.